Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.81, down 0.13% with a bearish technical signal. The fund maintains a low 0.03% expense ratio and offers monthly dividend distributions, with recent payouts around $0.33-$0.34. Technical indicators show oversold conditions with RSI at 19.28, while moving averages signal bearish momentum. The fund provides exposure to over 2,000 investment-grade corporate bonds with a current SEC yield around 5.17%.

VCIT offers income-focused investors a balanced approach to intermediate-term corporate bonds with competitive yields and low costs. Key risks include interest rate sensitivity and corporate credit quality concerns. The fund's diversification across investment-grade issuers provides stability, though economic uncertainty could impact bond valuations. Current technical weakness may present entry opportunities for yield-seeking investors.